We conduct investigational and discovery research on our proprietary neural stem cell lines, neurogenic small molecule screening platform, and neurogenic small molecule portfolio. These technologies enable us to identify unique neural stem cell lines for potential transplantation therapies and to utilize these stem cell lines to screen for novel small molecule drugs. NSI-189 is a result of this screening technology, which we believe will be a significant treatment option for patients with depression or cognitive impairment.
Our research and development is supported by our intellectual property. We own or exclusively license over 20 U.S. issued and pending patents and over 120 foreign issued and pending patents in the field of regenerative medicine, related to our stem cell technologies as well as our small molecule compounds. Our issued patents have expiration dates ranging from 2016 through 2035.